A new risk score for patients after first recurrence of stage 4 neuroblastoma aged ≥18 months at first diagnosis
A new risk score for patients after first recurrence of stage 4 neuroblastoma aged ≥18 months at first diagnosis
K. Kreitz,A. Ernst,5 Authors,F. Berthold
2019 · DOI: 10.1002/cam4.2562
Cancer Medicine · 14 Citations
TLDR
This study aims to define clinically useful risk criteria for treating patients with recurrences from stage 4 neuroblastoma and finds that it is necessary to consider the individual risks of the treated patients.
Abstract
The prognosis of patients with recurrences from stage 4 neuroblastoma is not uniformly dismal. The evaluation of new therapies therefore needs to consider the individual risks of the treated patients. This study aims to define clinically useful risk criteria.